EP1159414A1 - Verfahren zur steigerung der durch ein elektrisches feld vermittelten einbringung biologischen materials in zellen - Google Patents
Verfahren zur steigerung der durch ein elektrisches feld vermittelten einbringung biologischen materials in zellenInfo
- Publication number
- EP1159414A1 EP1159414A1 EP00964909A EP00964909A EP1159414A1 EP 1159414 A1 EP1159414 A1 EP 1159414A1 EP 00964909 A EP00964909 A EP 00964909A EP 00964909 A EP00964909 A EP 00964909A EP 1159414 A1 EP1159414 A1 EP 1159414A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- biological material
- electric field
- cells
- biological
- binding reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 239000012620 biological material Substances 0.000 title claims abstract description 61
- 230000005684 electric field Effects 0.000 title claims description 74
- 230000008569 process Effects 0.000 title description 7
- 230000002708 enhancing effect Effects 0.000 title description 2
- 230000001404 mediated effect Effects 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 79
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 79
- 239000002157 polynucleotide Substances 0.000 claims abstract description 79
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 76
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 229920001222 biopolymer Polymers 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 230000002195 synergetic effect Effects 0.000 claims abstract description 19
- 230000030833 cell death Effects 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 238000001890 transfection Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 108090000994 Catalytic RNA Proteins 0.000 claims description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 108091092562 ribozyme Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- -1 cationic lipid Chemical class 0.000 claims description 4
- 108020000999 Viral RNA Proteins 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229920000620 organic polymer Polymers 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108020005202 Viral DNA Proteins 0.000 claims description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 2
- 150000001720 carbohydrates Chemical group 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 108010055896 polyornithine Proteins 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 98
- 238000004520 electroporation Methods 0.000 abstract description 39
- 210000000170 cell membrane Anatomy 0.000 abstract description 16
- 238000001727 in vivo Methods 0.000 abstract description 15
- 238000012546 transfer Methods 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 7
- 238000001415 gene therapy Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 238000012239 gene modification Methods 0.000 abstract description 4
- 230000005017 genetic modification Effects 0.000 abstract description 4
- 235000013617 genetically modified food Nutrition 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 30
- 239000011148 porous material Substances 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000003071 parasitic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005370 electroosmosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000242679 Schistosoma bovis Species 0.000 description 2
- 241000242677 Schistosoma japonicum Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 102000003848 Uteroglobin Human genes 0.000 description 2
- 108090000203 Uteroglobin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 241001233887 Ania Species 0.000 description 1
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000238678 Boophilus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000243990 Dirofilaria Species 0.000 description 1
- 108700010895 Drosophila ADH Proteins 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101710093554 Galactose-specific lectin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 101710178393 Globin-like protein Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000033866 Rare inborn errors of metabolism Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000243796 Trichostrongylus colubriformis Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108091000100 Tyrosine Phenol-Lyase Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- BOJOZZSCQUTEBY-IXMYILBSSA-N [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (3S)-dithiolane-3-carboxylate Chemical compound O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)[C@H]1SSCC1 BOJOZZSCQUTEBY-IXMYILBSSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- biological materials such as polynucleotides or other biopolymers
- charged organic polymers that are employed include, but are not limited to, polycationic amino polymers, poly L-lysines, polyamidoamine dendrimers, jpolyethyleneimine, polyethanolamine, and poly-L-ornithine and dendrimer, oligomers, and copolymers thereof.
- an “endogenous gene” means a polynucleotide encoding a protein or part thereof or antisense RNA or catalytic RNA which is naturally present in the recipient animal cell or tissue.
- the polynucleotide of interest encodes a vaccine antigen.
- the term "vaccine antigen” refers to an agent capable of stimulating the immune system of a living organism, inducing the production of an increased level of antibodies, the production of a cellular immune response, or the activation other immune responsive cells involved in the immune response pathway against said antigen.
- the vaccine antigen expression may be performed to elicit an immune response and/or to induce tolerance to the encoded antigen.
- expression of antigens in cells which lack co-stimulatory molecule expression can enable the development of tolerance to the antigen.
- the parasitic pathogens from which the parasitic antigens are derived, include but are not limited to, Plasmodium spp., Trypanosome spp., Giardia spp., Boophilus spp., Babesia spp., Enta oeba spp., Eimeria spp., Leish ania spp., Schistosome spp., Brugin spp., Fascida spp., Dirofilaria spp., Wuchereria spp., and Onchocerea spp ..
- protective antigens of parasitic pathogens include the circumsporozoite antigens of Plasmodium spp.
- dose-response experiments can be used to determine efficacy, toxicity, and effective dose of a particular polynucleotide preparation and polynucleotide binding reagent . Such experiments are routine in the art and well within the skill of one with ordinary skill in the art .
- Heat production within the solution is exponentially proportional to electrical current within the solution.
- the cooling is not rapid enough to compensate for the rapid rise in temperature related to excessive electrical current.
- Tables I and II Still further novel, surprising, unexpected, and inventive synergistic findings of the present invention are presented in Tables I and II. More specifically, as shown Table I in the entry in the third vertical column and the second horizontal row, indicated by the bracketed [EH] , when a conventionally low amount of binding reagents is employed in combination with a conventionally optimum amount of electric field imposition, a synergistically extra high level of cell transfection efficiency occurs. Similarly, as shown in Table II in the entry in the third vertical column and the second horizontal row, indicated by the bracketed [VL] , when a conventionally low amount of binding reagents is employed in combination with a conventionally optimum amount of electric field imposition, a synergistically very low level of cell death occurs .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15564099P | 1999-09-24 | 1999-09-24 | |
| US155640P | 1999-09-24 | ||
| PCT/US2000/021982 WO2001023537A1 (en) | 1999-09-24 | 2000-09-25 | Process for enhancing electric field-mediated delivery of biological materials into cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1159414A1 true EP1159414A1 (de) | 2001-12-05 |
| EP1159414A4 EP1159414A4 (de) | 2003-08-27 |
Family
ID=22556208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00964909A Withdrawn EP1159414A4 (de) | 1999-09-24 | 2000-09-25 | Verfahren zur steigerung der durch ein elektrisches feld vermittelten einbringung biologischen materials in zellen |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1159414A4 (de) |
| CA (1) | CA2390716A1 (de) |
| WO (1) | WO2001023537A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051454A2 (en) * | 2001-12-14 | 2003-06-26 | Genetronics, Inc. | Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| BRPI0611534A2 (pt) | 2005-05-12 | 2010-09-21 | Novartis Ag | genes e proteìnas da brachyspira hyodysenteriae e uso das mesmas para diagnose e terapia |
| MX2010001381A (es) | 2007-08-03 | 2010-09-14 | Spirogene Pty Ltd | Genes y proteinas de brachyspira hyodysenteriae y usos de los mismos. |
| GB0720250D0 (en) | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| EP2363407A1 (de) | 2008-02-28 | 2011-09-07 | Murdoch University | Neuartige Brachyspira-Sequenzen, immunogene Zusammensetzungen, Herstellungsverfahren dafür und Verwendung davon |
| AU2009227986C1 (en) | 2008-03-27 | 2014-06-19 | Murdoch University | Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424688A2 (de) * | 1989-09-28 | 1991-05-02 | Iowa State University Research Foundation, Inc. | Synergistisches Verfahren zur Wirtszellentransformation |
| WO1993019768A1 (en) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
| WO1996040961A1 (en) * | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5945400A (en) * | 1995-02-17 | 1999-08-31 | Rhone-Poulenc Rorer Sa | Nucleic acid-containing composition, preparation and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69727500T2 (de) * | 1997-06-10 | 2004-10-07 | Cyto Pulse Sciences Inc | Verfahren und apparatur zur behandlung von material mit elektrischen feldern unterschiedlicher orientierung |
-
2000
- 2000-09-25 EP EP00964909A patent/EP1159414A4/de not_active Withdrawn
- 2000-09-25 WO PCT/US2000/021982 patent/WO2001023537A1/en not_active Application Discontinuation
- 2000-09-25 CA CA002390716A patent/CA2390716A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424688A2 (de) * | 1989-09-28 | 1991-05-02 | Iowa State University Research Foundation, Inc. | Synergistisches Verfahren zur Wirtszellentransformation |
| WO1993019768A1 (en) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
| US5945400A (en) * | 1995-02-17 | 1999-08-31 | Rhone-Poulenc Rorer Sa | Nucleic acid-containing composition, preparation and use thereof |
| WO1996040961A1 (en) * | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5736392A (en) * | 1995-06-07 | 1998-04-07 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
Non-Patent Citations (15)
| Title |
|---|
| BABA MIYAKO ET AL: "In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats." INTERNATIONAL JOURNAL OF CANCER., vol. 85, no. 2, 15 January 2000 (2000-01-15), pages 260-266, XP002245188 ISSN: 0020-7136 * |
| BOUSSIF O ET AL: "A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN VIVO: POLYETHYLENIMINE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 16, August 1995 (1995-08), pages 7297-7301, XP002006502 ISSN: 0027-8424 * |
| CHERNOMORDIK L V ET AL: "INCREASED BINDING OF LIPOSOMES TO CELLS BY ELECTRIC TREATMENT" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1070, no. 1, 1991, pages 193-197, XP009012350 ISSN: 0006-3002 * |
| COULBERSON A L ET AL: "Gene packaging with lipids, peptides and viruses inhibits transfection by electroporation in vitro" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 86, no. 2-3, 17 January 2003 (2003-01-17), pages 361-370, XP004401129 ISSN: 0168-3659 * |
| FELGNER P L: "PARTICULATE SYSTEMS AND POLYMERS FOR IN VITRO AND IN VIVO DELIVERY OF POLYNUCLEOTIDES" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 5, no. 3, 1 September 1990 (1990-09-01), pages 163-187, XP000603153 ISSN: 0169-409X * |
| GAO X ET AL: "CATIONIC LIPOSOME-MEDIATED GENE TRANSFER" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 2, no. 10, 1 December 1995 (1995-12-01), pages 710-722, XP000749400 ISSN: 0969-7128 * |
| GODBEY W T ET AL: "Poly(ethylenimine) and its role in gene delivery" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 60, no. 2-3, 5 August 1999 (1999-08-05), pages 149-160, XP004362929 ISSN: 0168-3659 * |
| LEDLEY F D: "NONVIRAL GENE THERAPY: THE PROMISE OF GENES AS PHARMACEUTICAL PRODUCTS" HUMAN GENE THERAPY, XX, XX, vol. 6, September 1995 (1995-09), pages 1129-1144, XP001007448 ISSN: 1043-0342 * |
| MACCARRONE M ET AL: "Gene transfer to lentil protoplasts by lipofection and electroporation" JOURNAL OF LIPOSOME RESEARCH 1993 UNITED STATES, vol. 3, no. 3, 1993, pages 707-716, XP009012606 ISSN: 0898-2104 * |
| MACHY P ET AL: "Gene transfer from targeted liposomes to specific lymphoid cells by electroporation." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES NOV 1988, vol. 85, no. 21, November 1988 (1988-11), pages 8027-8031, XP001152921 ISSN: 0027-8424 * |
| MACK K D ET AL: "A novel method for DEAE-dextran mediated transfection of adherent primary cultured human macrophages" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 211, no. 1-2, 1998, pages 79-86, XP004120571 ISSN: 0022-1759 * |
| SAWAI KEISUKE ET AL: "A novel method of cell-specific mRNA transfection." MOLECULAR GENETICS AND METABOLISM, vol. 64, no. 1, May 1998 (1998-05), pages 44-51, XP002245185 ISSN: 1096-7192 * |
| See also references of WO0123537A1 * |
| SPOERLEIN B ET AL: "LIPOFECTIN DIRECT GENE TRANSFER TO HIGHER PLANTS USING CATIONIC LIPOSOMES" THEORETICAL AND APPLIED GENETICS, vol. 83, no. 1, 1991, pages 1-5, XP009012649 ISSN: 0040-5752 * |
| WELLS J M ET AL: "ELECTROPORATION-ENHANCED GENE DELIVERY IN MAMMARY TUMORS" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 7, April 2000 (2000-04), pages 541-547, XP008010350 ISSN: 0969-7128 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2390716A1 (en) | 2001-04-05 |
| EP1159414A4 (de) | 2003-08-27 |
| WO2001023537A1 (en) | 2001-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Young et al. | Electroporation-mediated gene delivery | |
| Jechlinger | Optimization and delivery of plasmid DNA for vaccination | |
| Mehier-Humbert et al. | Physical methods for gene transfer: improving the kinetics of gene delivery into cells | |
| Manoj et al. | Approaches to enhance the efficacy of DNA vaccines | |
| Hasan et al. | Nucleic acid immunization: concepts and techniques associated with third generation vaccines | |
| Heller et al. | Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation | |
| Escoffre et al. | Gene transfer: how can the biological barriers be overcome? | |
| Běláková et al. | DNA vaccines: are they still just a powerful tool for the future? | |
| DE69929470T2 (de) | Genkonstrukte für genimmunisierung | |
| Wang et al. | DNA immunization | |
| Haynes et al. | Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization | |
| Choi et al. | Topical DNA vaccination with DNA/Lipid based complex | |
| EP1159414A1 (de) | Verfahren zur steigerung der durch ein elektrisches feld vermittelten einbringung biologischen materials in zellen | |
| US11179458B2 (en) | Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus | |
| Keane-Myers et al. | Evolution of electroporated DNA vaccines | |
| Preat et al. | Topical delivery of nucleic acids in the skin | |
| N Gupta et al. | Colloidal carrier systems for transcutaneous immunization | |
| Accensi et al. | DNA Vaccines in Pigs: From Immunization to Antigen Identification | |
| US20190307704A1 (en) | Method for enhanced delivery of gene based therapy and vaccination using electroporation | |
| Hasan | Messenger RNA Based Vaccines and Their immunological effect on diseases | |
| Littel-van den Hurk | Novel methods for the non-invasive administration of DNA therapeutics and vaccines | |
| US20040009947A1 (en) | Compounds and methods for enhancing delivery of free polynucleotide | |
| Barry et al. | Gene Gun technologies: applications for gene therapy and genetic immunization | |
| AU5568499A (en) | Compounds and methods for enhancing delivery of free polynucleotide | |
| Omaji et al. | DNA VACCINES: CHALLENGES AND APPROACHES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20011005 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 15/87 B Ipc: 7C 12N 15/85 B Ipc: 7C 12N 15/70 B Ipc: 7C 12N 15/82 B Ipc: 7C 12N 15/00 A |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20030710 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20050402 |